Steven Cohen’s MoonLake Immunotherapeutics MLTX Stock Holding History

Steven Cohen’s Portfolio MLTX Stock Details MLTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$22.6M	Sell	1,158,732 -209,786	-15%	-$3.8M	0.02%	815
2026 Q1	$25.5M	Buy	1,368,518 +596,018	+77%	+$9.87M	0.03%	681
2025 Q4	$10.2M	Buy	772,500 +762,700	+7,783%	+$9M	0.01%	1347
2025 Q3	$70.3K	Sell	9,800 -176,768	-95%	-$9.21M	﹤0.01%	2222
2025 Q2	$8.81M	Buy	+186,568	New	+$7.6M	0.02%	781
2025 Q1	–	Sell	-98,719	Closed	-$5.35M	–	2345
2024 Q4	$5.35M	Buy	+98,719	New	+$5.04M	0.01%	926
2023 Q2	–	Sell	-29,748	Closed	-$636K	–	2538
2023 Q1	$636K	Buy	+29,748	New	+$500K	﹤0.01%	1186
2022 Q4	–	Sell	-335,000	Closed	-$2.6M	–	1689
2022 Q3	$2.6M	Buy	+335,000	New	+$2.37M	0.01%	868
2021 Q1	–	Sell	-70,000	Closed	-$796K	–	1094
2020 Q4	$796K	Buy	+70,000	New	+$743K	﹤0.01%	825

Other funds holding MLTX

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

Jupiter Topco New York $245B AUM

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

WAM

Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Steven Cohen's MLTX Position: Q2 2026 in Review

Steven Cohen reduced its MoonLake Immunotherapeutics (MLTX) stake by 15% in Q2 2026, selling an estimated $3.8M and leaving 1,158,732 shares worth $22.6M. The position accounts for 0.02% of the portfolio, ranked #815.

Steven Cohen first reported a position in MLTX in Q4 2020 and has held it in 9 quarters since. The position peaked at $25.5M in Q1 2026. 171 funds tracked by Wall St. Rank hold MLTX as of Q2 2026.

Steven Cohen held 1,158,732 shares of MoonLake Immunotherapeutics worth $22.6M as of Q2 2026.
Steven Cohen sold 209,786 MoonLake Immunotherapeutics shares in Q2 2026, an estimated $3.8M.
MoonLake Immunotherapeutics made up 0.02% of Steven Cohen's portfolio in Q2 2026, its #815 holding.
Steven Cohen first reported a position in MoonLake Immunotherapeutics in Q4 2020 and has held it in 9 quarters since.
Steven Cohen's MoonLake Immunotherapeutics position peaked at $25.5M in Q1 2026.
171 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q2 2026.

Based on Point72 Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.